INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors
NCT ID: NCT04436679
Last Updated: 2025-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
342 participants
OBSERVATIONAL
2021-02-02
2025-02-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616
Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma
NCT06478056
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors
NCT05794048
SERum-bank for PANcreatic Cancer
NCT04374175
Prognostic and Predictive Markers of Treatment Response in Patients With PAC.
NCT05776342
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary pancreatic cancer patients operated on in one of the 4 centres between 2001 and 2016
* Histopathological diagnosis of excreto-pancreatic adenocarcinoma of the pancreas, ductal adenocarcinoma or classical adenocarcinoma
* Tissue blocks (FFPE) available (tumour/healthy tissue)
* Affiliated to a social security scheme
Exclusion Criteria
* Paraffin block fixed in Bouin or AFA
* Patient Refusal
* Pancreatic cancer not corresponding to a conventional excretopancreatic adenocarcinoma such as: carcinoma on intraductal papillary mucinous neoplasm, endocrine tumor/carcinoma, acinar cell carcinoma, ...).
* Patient died due to post-surgical complications (death within 30 days post-surgery).
* Surgical resection of macroscopic R2 type.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emmanuelle Leteurtre, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hop Claude Huriez Chu Lille
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A02001-56
Identifier Type: OTHER
Identifier Source: secondary_id
2019_29
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.